INCY â Q2 Beats Street On Jakafi & Raises 2013 Forecast, Burgeoning Pipeline â Raising BUY LIMIT and PRICE TARGET. The key near-term driver for INCY is Jakafi growth and with the increased sales guidance, the company is delivering. The drug’s overall profile continues to improve as witnessed by label expansion for patients with low[…]
To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.